15 research outputs found
A Phenomenological Analysis of Gluon Mass Effects in Inclusive Radiative Decays of the and $\Upsilon
The shapes of the inclusive photon spectra in the processes \Jp \to \gamma
X and \Up \to \gamma X have been analysed using all available experimental
data.
Relativistic, higher order QCD and gluon mass corrections were taken into
account in the fitted functions. Only on including the gluon mass corrections,
were consistent and acceptable fits obtained. Values of
GeV and GeV were found for the
effective gluon masses (corresponding to Born level diagrams) for the \Jp and
\Up respectively. The width ratios \Gamma(V \to {\rm hadrons})/\Gamma(V \to
\gamma+ {\rm hadrons}) V=\Jp, \Up were used to determine and . Values consistent with the current world
average were obtained only when gluon mass correction factors,
calculated using the fitted values of the effective gluon mass, were applied. A
gluon mass GeV, as suggested with these results, is consistent with
previous analytical theoretical calculations and independent phenomenological
estimates, as well as with a recent, more accurate, lattice calculation of the
gluon propagator in the infra-red region.Comment: 50 pages, 11 figures, 15 table
Surgical treatment of patients with acute cholecystitis: Tokyo Guidelines
Cholecystectomy has been widely performed in the treatment of acute cholecystitis, and laparoscopic cholecystectomy has been increasingly adopted as the method of surgery over the past 15 years. Despite the success of laparoscopic cholecystectomy as an elective treatment for symptomatic gallstones, acute cholecystitis was initially considered a contraindication for laparoscopic cholecystectomy. The reasons for it being considered a contraindication were the technical difficulty of performing it in acute cholecystitis and the development of complications, including bile duct injury, bowel injury, and hepatic injury. However, laparoscopic cholecystectomy is now accepted as being safe for acute cholecystitis, when surgeons who are expert at the laparoscopic technique perform it. Laparoscopic cholecystectomy has been found to be superior to open cholecystectomy as a treatment for acute cholecystitis because of a lower incidence of complications, shorter length of postoperative hospital stay, quicker recuperation, and earlier return to work. However, laparoscopic cholecystectomy for acute cholecystitis has not become routine, because the timing and approach to the surgical management in patients with acute cholecystitis is still a matter of controversy. These Guidelines describe the timing of and the optimal surgical treatment of acute cholecystitis in a question-and-answer format
Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
Therapeutics based on RNA interference (RNAi) have emerged as a potential new class of drugs for treating human disease by silencing the target messenger RNA (mRNA), thereby reducing levels of the corresponding pathogenic protein. The major challenge for RNAi therapeutics is the development of safe delivery vehicles for small interfering RNAs (siRNAs). We previously showed that cholesterol-conjugated siRNAs (chol-siRNA) associate with plasma lipoprotein particles and distribute primarily to the liver after systemic administration to mice. We further demonstrated enhancement of silencing by administration of chol-siRNA pre-associated with isolated high-density lipoprotein (HDL) or low-density lipoprotein (LDL). In this study, we investigated mimetic lipoprotein particle prepared from recombinant apolipoprotein A1 (apoA) and apolipoprotein E3 (apoE) as a delivery vehicle for chol-siRNAs. We show that apoE-containing particle (E-lip) is highly effective in functional delivery of chol-siRNA to mouse liver. E-lip delivery was found to be considerably more potent than apoA-containing particle (A-lip). Furthermore, E-lip–mediated delivery was not significantly affected by high endogenous levels of plasma LDL. These results demonstrate that E-lip has substantial potential as delivery vehicles for lipophilic conjugates of siRNAs.ISSN:1525-0016ISSN:1525-002